Table 1 Patient, cancer and surgery characteristics
Variable | Total | Mayo 0-II | Mayo III-IV | P value |
|---|---|---|---|---|
N (%) | 121 | 95 (79) | 26 (21) | |
Median Age (IQR), years | 60 (53–67) | 59 (53–67) | 62 (52.8–68) | 0.475 |
Sex, n (%) | ||||
Male | 91 (75) | 73 (77) | 18 (69) | 0.426 |
Female | 30 (25) | 22 (23) | 8 (31) | |
Median BMI (IQR), kg/m2 | 23.3 (21–26) | 23 (20.8–26.6) | 23.6 (21.6–24.9) | 0.714 |
Tumor side, n (%) | 0.912 | |||
Left | 43 (36) | 34 (36) | 9 (35) | |
Right | 78 (64) | 61 (64) | 17 (65) | |
ASA level, n (%) | < 0.001 | |||
I + II | 95 (79) | 84 (88) | 11 (42) | |
III + IV | 26 (21) | 11 (12) | 15 (58) | |
Symptoms at presentation, n (%) | 0.011 | |||
No symptoms | 27 (22) | 26 (27) | 1 (4.0) | |
Symtemic/local symptoms | 94 (78) | 69 (73) | 25 (96) | |
Median tumor size (IQR), cm | 8 (6–11) | 7.3 (5.9–10.6) | 8.3 (6–11) | 0.246 |
Clinical T stage, n (%) | < 0.001 | |||
T3a | 24 (20) | 24 (25) | 0 (0) | |
T3b | 48 (40) | 44 (46) | 4 (15) | |
T3c | 39 (32) | 23 (24) | 16 (62) | |
T4 | 10 (8.0) | 4 (4.2) | 6 (23) | |
Surgical methods, n (%) | 0.413 | |||
Laparoscopic | 50 (41) | 49 (52) | 1 (4.0) | |
Open | 71 (59) | 46 (48) | 25 (96) | |
Conversion to open, n (%) | 0.118 | |||
Yes | 14 (22) | 12 (20) | 2 (67) | |
No | 50 (78) | 49 (80) | 1 (33) | |
Nuclear grade, n (%) | 0.254 | |||
Grade 1 + 2 | 49 (40) | 41 (43) | 8 (31) | |
Grade 3 + 4 | 72 (60) | 54 (57) | 18 (69) | |
Histological type, n (%) | 0.236 | |||
Clear-cell carcinoma | 102 (84) | 82 (86) | 20 (77) | |
Non-clear cell carcinoma | 19 (16) | 13 (14) | 6 (23) | |
Cardiopulmonary bypass, n (%) | 4 (3.3) | 1 (1.1) | 3 (12) | 0.031 |
Segmental IVC resection, n (%) | 23 (19) | 15 (16) | 8 (31) | 0.109 |
Median EBL (IQR), mL | 700 (200–2550) | 500 (200–1600) | 2550 (1500–4125) | < 0.001 |
Median RBC transfusion (IQR), mL | 400 (0–1600) | 0 (0–1200) | 1600 (1200–2500) | < 0.001 |
Median plasma transfusion (IQR), mL | 0 (0–600) | 0 (0–400) | 700 (350–1200) | < 0.001 |
Median operative time (IQR), min | 338 (242–444) | 311 (228–404) | 438 (372–520) | < 0.001 |
Perinephric fat invasion, n (%) | 39 (32) | 33 (35) | 6 (23) | 0.260 |
Sinus fat invasion, n (%) | 112 (93) | 88 (93) | 24 (92) | 0.956 |
Tumor necrosis, n (%) | 67 (55) | 50 (53) | 17 (65) | 0.246 |
Sarcomotoid differentiation, n (%) | 28 (23) | 20 (21) | 8 (31) | 0.298 |
Metastatic disease at resection, n (%) | 31 (26) | 25 (26) | 6 (23) | 0.737 |
Positive lymph node, n (%) | 19 (16) | 13 (14) | 6 (23) | 0.243 |
Adjuvant therapy, n (%) | 57 (47) | 44 (46) | 13 (50) | 0.739 |
ICU admission, n (%) | 87 (72) | 62 (65) | 25 (96) | 0.002 |
Median length of hospital-stay (IQR), days | 9 (6–13) | 9 (6–11) | 12.5 (8.8–16.3) | 0.004 |